TELA Bio Reports Q2 Revenue Decline, Increased Loss, and Withdraws Full-Year Guidance Amid Financial Distress
TELA sits 86% above its 52-week low of $0.501 on elevated volume (3.4× avg).
Summary
TELA Bio reported a 4% revenue decline and increased net loss for Q2, leading the new CEO to withdraw full-year guidance and signal upcoming actions to extend the cash runway and cut costs.
Updates
· SEC 10-Q — The 10-Q adds a going concern warning and discloses a potential covenant breach under the Perceptive term loan.
Key Events · Earnings and Guidance · TELA
-
Q2 Financial Miss
TELA Bio reported a 4% year-over-year revenue decline to $19.3 million and an increased net loss of $11.3 million for the second quarter.
-
Full-Year Guidance Withdrawn
The company, under its new CEO, withdrew its full-year 2026 revenue guidance, citing the need for a full business assessment.
-
Continued Financial Distress
The balance sheet shows negative stockholders' equity of $(15.9) million and cash of $30.4 million, highlighting ongoing financial challenges.
-
Cost Restructuring Imminent
Newly appointed CEO Heather Getz announced plans for "decisive action to extend our cash runway and better align our cost structure with our top line."
Analysis · TELA · Industrial Applications And Services
TELA Bio's Q2 results show continued revenue decline and an increased net loss, exacerbating its already precarious financial position, which includes negative stockholders' equity and a Nasdaq delisting notice. The new CEO's immediate withdrawal of full-year guidance signals significant uncertainty and the need for drastic measures to extend the company's cash runway and restructure costs. This indicates a challenging outlook and potential for further dilutive actions or operational changes.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TELA was trading at $0.93 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $41.6M. The 52-week trading range was $0.50 to $2.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.